Document is current
Any future updates will be listed below
-
Authors
Sugihara, Takahiko https://orcid.org/0000-0002-7181-7494
Harigai, Masayoshi
Uchida, Haruhito A.
Yoshifuji, Hajime
Maejima, Yasuhiro
Ishizaki, Jun
Watanabe, Yoshiko
Dobashi, Hiroaki
Komagata, Yoshinori
Tamura, Naoto
Nakaoka, Yoshikazu
,
Tanaka, Yoshiya
Takeuchi, Tsutomu
Naniwa, Taio
Nagafuchi, Hiroko
Okazaki, Takahiro
Horita, Tetsuya
Atsumi, Tatsuya
Arimura, Yoshihiro
Isobe, Mitsuaki
Tanemoto, Kazuo
Ogawa, Noriyoshi
Murakawa, Yohko
Furuta, Shunsuke
Hasegawa, Hitoshi
Katsumata, Yasuhiro
Amiya, Eisuke
Akazawa, Hiroshi
Komuro, Issei
Amano, Koichi
Kawakami, Atsushi
Kobayashi, Shigeto
Wada, Takashi
Muso, Eri
Komatsuda, Atsushi
Ito, Satoshi
Homma, Noriyuki
Hayashi, Taichi
Takeda, Shinichi
Wada, Takashi
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019, H29-nanchitou (nan)-ippan-018, 20FC1044, and 23FC1019)
Japan Agency for Medical Research and Development (JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002, JP17ek0109121 and 24ek0109633h0002)
Ministry of Education, Culture, Sports, Science and Technology (23K09729)
- License Information
-
More Information
Article History
Received: 2 December 2024
Accepted: 23 January 2025
First Online: 31 January 2025
Declarations
:
: This study was conducted following the Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research in Japan. The institutional review board of Tokyo Medical and Dental University as the main center (approval number: M2000-2084-01) and the additional 23 institutions approved our retrospective study without personally identifiable information. Patients received posters informing the present study, or the posters were displayed in the outpatient clinic of each facility.
: Not applicable.
: TS has received research grants from AsahiKASEI Co., Ltd., Daiichi Sankyo., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical. TS has received speaker’s fee from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., and Taisho Pharmaceutical Co., Ltd.. MH has received research grants from Boehringer-Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Teijin Pharma Ltd. MH has received speaker’s fee from Boehringer-Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Teijin Pharma Ltd. MH is a consultant for Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd. and Teijin Pharma. HAU belongs to the Department of Chronic Kidney Disease and Cardiovascular Disease which is endowed by Olba Healthcare Holdings, Boehringer Ingelheim, and Terumo Corporation. HY has received lecture fees from Chugai Pharmaceutical and consulting fees from Janssen. HD has received speaking fees, and/or honoraria from Abbvie, Asahi Kasei Pharma, Astellas, UCB Pharmaceutical, Ayumi Pharmaceutical, GlaxoSmithKline, Novartis Pharma, Eli Lilly Japan, and AstraZeneca. YK has received speaker’s fee from GlaxoSmithKline. NT has received research grants from Asahi Kasei Pharma, Asahi Kasei Medical, Ayumi, AbbVie, Eisai, Nippon Boehringer Ingelheim, Taisho, Tanabe Mitsubishi, Chugai. NT has received speaker’s fee and/or consulting fee from Asahi Kasei Pharma, AstraZeneca, AbbVie, Eli Lilly Japan, GlaxoSmithKline, Chugai, Novartis, Bristol Myers Squibb, Janssen. YN has received consulting fees from AbbVie, Janssen Pharmaceutical KK, and Chugai, and has received lecture fees from AbbVie and Chugai. YM, JI and YW has nothing to declare.
